Upcoming Presentations
Due to popular demand, all of our monthly presentations are now open access to everyone. Only VCCIS members in good standing will receive CE credit for attending the live presentation.
Regulation of host-microbiota dynamics at the intestinal interface during health, infection, and inflammation hosted by Dr. Seika Hashimoto-Hill January 15, 2026 4:00 pm Eastern (1 CE credit)
Modernized Drug Development: Monoclonal Antibodies hosted by Dr. Nikki Thellman February 19, 2026 4:00 pm Eastern (No CE credit)
Unlocking Cellular Heterogeneity in Veterinary Immunology: Single-Cell and Spatial Approaches hosted by Dr. Leilani Marty-Santos March 19, 2026 4:00 pm Eastern (1 CE credit)
Molecular markers of treatment response in dogs with IMHA and IMPA hosted by Dr. James Swann April 16, 2026 4:00 pm Eastern (1 CE credit)
Most of these programs have been approved for one (1) hour of continuing education credit in jurisdictions that recognize RACE approval. Credit may only be requested during the live presentation and will be awarded to VCCIS members in good standing only. On-demand viewing will not qualify for CE credit.
UPCOMING TRAINEE SEMINAR SERIES LECTURES
Seminar Series no 3: Innate immunity - Cytokines / chemokines, phagocytosis, mechanisms of cell death hosted by Dr. Caroline Griffin - VCCIS members only
VCCIS at the ACVIM Forum 2026 - June 2026, Seattle WA
- Vaccines and Vaccination Practices (one hour)
- Bovine Respiratory Disease: Challenges and Research Trends (30 minutes)
- Advances in Feline Vaccines: Coronavirus and Beyond (30 minutes)
VCCIS Special Interest Group (SIG) - June 11, 2026; 6:30 - 9:30 pm
- Linking Microbiome Dysbiosis and Inflammation: Therapeutic Implications for Chronic Inflammatory Enteropathies (RSVP)
Chronic inflammatory enteropathies (CE) occur very common in dogs and cats, and are frustrating to treat due to heterogenous treatment responses and lack of specific markers. The pathophysiology is complex and includes changes in the immune system, intestinal function, and the intestinal microbiome. The current classification based on treatment response (ie, food-, steroid-responsive) is currently being questioned, as new research findings indicate that CE is a progressive syndrome with many overlapping unspecific features, often due to chronic inflammation and irreversible mucosal remodeling, leading to changes in intestinal function and dysbiosis. The presentation will summarize novel research about the pathophysiology and novel concepts in multi-modal therapy, focusing on microbiome therapy, to these conditions. The presenter team will cover both findings from academic research and clinical experience from specialty practice in an interactive way.
Recorded Presentations
Please visit our Resource Library to view our recorded presentations.
